Venkatraman, N., et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

In Scientific Papers

Venkatraman, N., et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Lancet Microbe, 2025 Mar, 6(3):100868. PMID: 39805302

  • The study evaluates the safety and immunogenicity of the novel malaria vaccine candidate R21, administered with the Matrix-M adjuvant, in two phase 1 clinical trials conducted in the UK and Burkina Faso. The trials aimed to assess the tolerability of different doses of the vaccine and the resulting immune responses in malaria-naïve individuals and healthy adults from a high malaria transmission area.  
  • Results indicated that R21/Matrix-M elicited strong antibody responses and had an acceptable safety profile, with minimal reactogenicity and no significant post-vaccination fever, which is a crucial benefit for mass immunization campaigns. The study highlighted that the saponin-based Matrix-M adjuvant exhibited an improved safety profile compared to the RTS,S vaccine, which contains a different adjuvant (AS01E).  

Click here to access the full scientific paper.

 

Saponin Science Spotlight

Join Our Scientific Papers Newsletter

Please Select "I agree to receive email updates" options.

Email field is required to register.

Recent Posts

Start typing and press Enter to search